Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05123612

Maternal & Offspring Microbiome Study

The purpose of the study is to learn how different dietary interventions affect microbiota diversity in pregnant women and the transmission of microbiota to their infants during pregnancy, birth, and postpartum.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University

Stanford, California, 94305, United States

About this study

This research study aims to understand the relationship of dietary fiber, fermented foods, and the microbiome, specifically during pregnancy and postpartum. The investigators know that the composition of the microbiome can have an important effect on overall health, and a greater variety will confer more health benefits. Research suggests that maternal microbiota play an important role in the development of their offspring's microbiota during pregnancy, childbirth, and breastfeeding. The purpose of this study is to assess how diet impacts maternal microbiome during pregnancy and their infant's microbiome up to about two years postpartum.

Potential pregnant participants will be recruited during their first trimester up to 22 weeks. After completion of the baseline visit and sample collection, they will be randomized to start a diet high in fiber, high in fermented foods, high in both fiber and fermented foods, or a usual care group. Participants will be asked to provide blood, stool, vaginal swab, and breast milk samples periodically throughout the study. Cord blood will be collected after childbirth, and infant blood from a heel stick will be collected twice. They will also be asked to fill out online questionnaires and perform dietary recalls with study diet assessors.

After completing the study, participants will be invited to continue to participate in an extension of the study for approximately three and a half additional years. The purpose of this extension is to continue to assess how diet impacts the mother's microbiome postpartum and the child's microbiome up to about 5 years of age.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 18 years of age
  • Singleton pregnancies
  • Recruit during the first trimester and up to 22 weeks of pregnancy.
  • Healthy subjects willing and able to provide blood, stool, vaginal swab, and breast milk samples.
  • Must be able to provide signed and dated informed consent.

Exclusion criteria

  • Pre-pregnancy BMI greater than 40
  • Blood pressure SBP: > 160 mmHg -OR- DBP: > 90 mmHg
  • Kidney disease
  • Liver disease
  • Anemia
  • Symptomatic gallstones
  • History of bariatric surgery
  • Acute disease at time of enrollment (i.e. flu or gastroenteritis). May delay sampling until subject recovers.
  • Chronic, clinically significant, unstable (unresolved, requiring on-going changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history
  • History of active uncontrolled gastrointestinal disorders or diseases including:
  • Inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;
  • Irritable bowel syndrome (IBS) (moderate-severe);
  • Persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated)
  • Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection.
  • Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
  • Confirmed or suspected autoimmune disease

Medications:

  • Weight loss medications
  • Regular high dose aspirin
  • Regular use of prescription opiate pain medication

If taken in the past 2 months:

  • Systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular or oral)
  • Corticosteroids (intravenous, intramuscular, oral, nasal or inhaled)
  • Cytokines
  • Methotrexate or immunosuppressive cytotoxic agents

Diet & Lifestyle:

  • Recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or > 14 drinks/week.
  • Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products

Maternal chronic medical conditions:

  • Pre-gestational diabetes (T1 or T2)
  • History of gestational diabetes
  • On medication that is an immune modulators or chronic steroid use
  • Hyperemesis gravidarum

Pregnancy history:

  • Preterm birth
  • Recurrent pregnancy loss

Treatment and study plan

Fiber

Behavioral

Additional 20 grams of fiber/day.

Fermented Foods

Behavioral

6 servings of fermented foods/day

Primary outcomes

  1. Difference in total number of species detected in stool as a measure of infant microbiota diversity.

    Time frame: 1 month postpartum

    Difference in total number of species (ASVs - Amplicon Sequence Variants) detected in stool between the fiber, fermented, fiber + fermented and comparator arms at 1 month postpartum.

Secondary outcomes

  1. Change in the total number of species detected in stool as a measure of maternal microbiota diversity.

    Time frame: Baseline and 36 weeks of pregnancy

    Change in differences in total number of species (ASVs- Amplicon Sequence Variants) detected in stool from baseline to 36 weeks of pregnancy between fiber, fermented, fiber + fermented, and comparator arms.

  2. Change in the maternal inflammatory marker profile

    Time frame: Baseline and 36 weeks of pregnancy

    Change in the differences in inflammatory markers (β-NGF, LIF-R, IL-12B, IL10, CASP-8, LAP TGF-β-1, CD6, CD5, MCP-2, IL6, CCL20, IL18, VEGFA, MMP-10, MCP-4, CCL4, CXCL10, CCL19, FGF-21) detected in blood samples from baseline to 36 weeks of pregnancy between fiber, fermented, fiber + fermented, and comparator arms.

  3. Characterize the infant inflammatory marker profile

    Time frame: 6 months postpartum

    Difference in amount of inflammatory markers (β-NGF, LIF-R, IL-12B, IL10, CASP-8, LAP TGF-β-1, CD6, CD5, MCP-2, IL6, CCL20, IL18, VEGFA, MMP-10, MCP-4, CCL4, CXCL10, CCL19, FGF-21) detected in heel stick blood between fiber, fermented, fiber + fermented, and comparator arms at 6 months postpartum.

  4. Characterize the infant allergy marker profile

    Time frame: 6 months postpartum

    Difference in amount of allergy markers (skin prick testing) detected in heel stick blood between fiber, fermented, fiber + fermented, and comparator arms at 6 months postpartum.

  5. Infant Growth

    Time frame: 18 months postpartum

    Difference in weight-for-length growth chart percentiles between fiber, fermented, fiber + fermented, and comparator arms at 18 months postpartum.

  6. Maternal Weight

    Time frame: 36 weeks of pregnancy

    Differences in the number of participants who gained weight within the pregnancy weight gain recommendations between fiber, fermented, fiber + fermented, and comparator arms measured at 36 weeks.

  7. Maternal systolic blood pressure

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in systolic blood pressure at 36 weeks of pregnancy.

  8. Maternal diastolic blood pressure

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in diastolic blood pressure at 36 weeks of pregnancy.

  9. Maternal LDL-cholesterol

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in LDL cholesterol at 36 weeks of pregnancy.

  10. Maternal HDL-cholesterol

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in HDL cholesterol at 36 weeks of pregnancy.

  11. Maternal triglycerides

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in triglycerides at 36 weeks of pregnancy.

  12. Maternal glucose

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in glucose at 36 weeks of pregnancy.

  13. Maternal fasting insulin

    Time frame: Baseline and 36 weeks of pregnancy

    Change from baseline in fasting insulin at 36 weeks of pregnancy.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Effects of Fermented & Fiber-rich Foods on Maternal & Offspring Microbiome Study

Acronym: MOMS

Important dates

Study start
2022
Primary completion
2029
Study completion
2029
First posted
Nov 17, 2021
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.